지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 저널정보
- 대한외과학회 Annals of Surgical Treatment and Research Annals of Surgical Treatment and Research Vol.94 No.5
- 발행연도
- 2018.5
- 수록면
- 223 - 228 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Primary prophylaxis with granulocyte colony-stimulating factor can effectively prevent febrile neutropenia (FN) during breast cancer treatment. The aims of this study were to evaluate the incidence of FN and the ANC profile in patients undergoing chemotherapy and pegfilgrastim primary prophylaxis.
Methods: Patients receiving 6 cycles of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy were included in this study. Pegfilgrastim was administered with analgesics 24 hours after treatment. Laboratory tests were performed on day 0 (before chemotherapy) and ANC was measured daily starting day 5 until it were restored to 1,000/㎣. Bone pain was checked via the numeral rating scale (NRS).
Results: A total of 61 patients and 366 cycles were evaluated. Mean age was 49.2 ± 7.1 years. FN was seen in 5 patients (16.4%) and 12 cycles (3.3%) with pegfilgrastim. Grades 3 and 4 neutropenia was seen in 91.5% of cycles with FN. The ANC nadir was most commonly seen at day 7 and the mean ANC nadir depth was 265.7/㎥. Age was negatively correlated with nadir depth (r = –0.137, P = 0.009). Severe pain higher than NRS 7 occurred in less than 20% of patients after the administration of pegfilgrastim.
Conclusion: Incidence of FN was low during the chemotherapy by primary prophylaxis with pegfilgrastim. The ANC nadir was seen on day 7 after chemotherapy. Bone pain with pegfilgrastim was well tolerated during TAC chemotherapy.
Methods: Patients receiving 6 cycles of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy were included in this study. Pegfilgrastim was administered with analgesics 24 hours after treatment. Laboratory tests were performed on day 0 (before chemotherapy) and ANC was measured daily starting day 5 until it were restored to 1,000/㎣. Bone pain was checked via the numeral rating scale (NRS).
Results: A total of 61 patients and 366 cycles were evaluated. Mean age was 49.2 ± 7.1 years. FN was seen in 5 patients (16.4%) and 12 cycles (3.3%) with pegfilgrastim. Grades 3 and 4 neutropenia was seen in 91.5% of cycles with FN. The ANC nadir was most commonly seen at day 7 and the mean ANC nadir depth was 265.7/㎥. Age was negatively correlated with nadir depth (r = –0.137, P = 0.009). Severe pain higher than NRS 7 occurred in less than 20% of patients after the administration of pegfilgrastim.
Conclusion: Incidence of FN was low during the chemotherapy by primary prophylaxis with pegfilgrastim. The ANC nadir was seen on day 7 after chemotherapy. Bone pain with pegfilgrastim was well tolerated during TAC chemotherapy.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (26)
참고문헌 신청
[학술지(정기간행물)] - Chirivella I / 2009 / Optimal delivery of anthracycline-based chemotherapy in the adjuvant setting improves outcome of breast cancer patients / Breast Cancer Res Treat 114 : 479 ~ 484
[학술지(정기간행물)] - Clark OA / 2005 / Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials / J Clin Oncol 23 : 4198 ~ 4214
[학술지(정기간행물)] - Aapro MS / 2011 / 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours / Eur J Cancer 47 : 8 ~ 32
[학술지(정기간행물)] - Crawford J / 2010 / Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications / Ann Oncol 21 (Suppl 5) : v248 ~ v251
[인터넷자원] - National Comprehensive Cancer Network / 2018 / NCCN clinical practice guidelines in oncology (NCCN Guidelines) [Internet]
[학술지(정기간행물)] - Clark OA / 2005 / Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials / J Clin Oncol 23 : 4198 ~ 4214
[학술지(정기간행물)] - Aapro MS / 2011 / 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapyinduced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours / Eur J Cancer 47 : 8 ~ 32
[학술지(정기간행물)] - Crawford J / 2010 / Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications / Ann Oncol 21 (Suppl 5) : v248 ~ v251
[인터넷자원] - National Comprehensive Cancer Network / 2018 / NCCN clinical practice guidelines in oncology (NCCN Guidelines) [Internet]
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
Journal of Breast Cancer
2020 .01
-
Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy
Annals of Surgical Treatment and Research
2021 .02
-
비호지킨림프종 환자의 발열성 호중구감소증에 대한 페그필그라스팀의 예방효과
한국임상약학회지
2015 .01
-
Chemotherapy : Is it needed?
대한외과학회 학술대회 초록집
2015 .11
-
Incidence, Risk Factors, and Outcomes of Febrile Neutropenia in Thai Hematologic Malignancy Patients Receiving Chemotherapy: A 6-year Retrospective Cohort Study
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Clinical Study on Safety and Efficacy of JiSaiXin (Recombinant Human Granulocyte Colony Stimulating Factor Injection Manufactured in China) for Chinese Undergoing Chemotherapy
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Incidence of Febrile Neutropenia in Advanced Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy in Korea and Its Impact on Prognosis
Journal of Breast Disease
2019 .01
-
Comparison of the Beneficial Effects of Adjuvant Chemotherapy among Young and Old Aged Breast Cancer Patients
Journal of Breast Disease
2019 .01
-
The efficacy of chemotherapy in the patients with stage II colon cancer associated with number of high-risk factors
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2018 .12
-
Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma
Cancer Research and Treatment
2022 .10
-
Adjuvant Chemotherapy
대한외과학회 학술대회 초록집
2021 .11
-
췌장 및 담도암 환자의 항암 시작, 반응 평가 및 항암 중단 시점
대한췌담도학회지
2020 .01
-
Quality of life changes during adjuvant chemotherapy in patients with colon cancer
KOREAN JOURNAL OF CLINICAL ONCOLOGY
2016 .06
-
Changes of Cognitive Function and Fatigue following Chemotherapy in Patients with Gastrointestinal Cancer: A Prospective Controlled Study
Asian Oncology Nursing
2019 .09
-
유방암 환자의 화학요법 치료시기에 따른 체중변화
기초간호자연과학회지
2016 .01
-
Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database
Yonsei Medical Journal
2021 .01
-
유방암 환자에서 항암화학요법 후 인지기능과 후각기능의 변화 : 예비연구
생물치료정신의학
2017 .06
-
Absolute Neutrophil Count after the First Chemotherapy Cycle as a Surrogate Marker for Treatment Outcomes in Patients with Neuroblastoma
Cancer Research and Treatment
2022 .01
-
The Prognostic Significance of Compliance with Postoperative Adjuvant Chemotherapy in Patients with Stage III Gastric Cancer: an Observational Study
Journal of Gastric Cancer
2018 .03
-
Chemotherapy and targeted therapy
대한외과학회 학술대회 초록집
2016 .11
이 논문의 저자 정보
최근 본 자료
댓글(0)
0